Participation in the Eastern Cooperative Oncology Group

参加东部肿瘤合作组

• 批准号: 7625133
• 负责人: JOSEPH AISNER
• 金额: $ 23.81万
• 依托单位: UNIV OF MED/DENT NJ-R W JOHNSON MED SCH
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-02 至 2010-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7625133
• 关键词: Area; Basic Science; Cancer Institute of New Jersey; Clinical; Clinical Research; Clinical Trials; Clinical Trials Cooperative Group; Collaborations; Commit; Comprehensive Cancer Center; Correlative Study; Data; Data Quality; Dentistry; Development; Diagnosis; Disease; Eastern Cooperative Oncology Group; Evaluation; Faculty; Funding; Grant; Growth; Hospitals; Institution; Laboratories; Leadership; Medicine; Modality; New Agents; New Brunswick; New Jersey; Operative Surgical Procedures; Patient Monitoring; Patients; Peer Review; Phase; Phase II Clinical Trials; Physicians; Pilot Projects; Positioning Attribute; Prevention; Protocol Compliance; Protocols documentation; Publications; Publishing; Radiation therapy; Research Personnel; Resources; Role; Science; Specialist; Translational Research; Universities; Wood material; Work; base; cancer education; chemotherapy; design; follow-up; medical schools; member; oncology; programs; symptom management

DESCRIPTION (provided by applicant): The Cancer Institute of New Jersey (CINJ) is an NCI Designated Comprehensive Cancer Center committed to the conduct of laboratory, clinical, and translational research relevant to cancer education, prevention, diagnosis and treatment. CINJ and our participation in ECOG have grown steadily since CINJ's recent inception, and we are committing even greater resources to ECOG in accrual (3year accrual of 284 and 434 follow-up), committee participation (17 committee participations), protocol leadership (7 active and 1 submitted study), and publications (23). CINJ also recently received approval as an ECOG Prevention Center, and as a member of the ECOG Symptom Management Consortium. Several of the CINJ investigators already received approval for NCI-funded ECOG correlative studies grants. Based on the continued growth of our patient base (>4000 new cases/year), the growth of our Affiliate Network (18 hospitals with >14,000 new cases), and our commitment to ECOG accrual in multiple disease areas, we expect our accrual, our scientific and our administrative roles to continue to grow. CINJ is thus positioned to become one of the larger main member contributors to the group. We propose to use this grant to: 1) continue our representation on ECOG disease oriented, administrative, and modality committees; 2) design and participate actively in new multi-modality studies; 3) offer peer reviewed, funded institutional laboratories as potential resources for group science; 4) monitor patient entry, protocol compliance, and data quality; 5) submit complete data forms in a timely manner, 6) continue development of pilot studies at the CINJ in collaboration with other ECOG members ; and 7) enhance interaction between the our basic science laboratories and the group's clinical trials program.

描述（由申请人提供）：新泽西癌症研究所（CINJ）是NCI指定的综合癌症中心，致力于开展与癌症教育，预防，诊断和治疗相关的实验室，临床和转化研究。 自CINJ最近成立以来，CINJ和我们在ECOG中的参与稳步增长，我们承诺在累积（3年累积284和434次随访）、委员会参与（17名委员会参与者）、方案领导（7项活动和1项提交的研究）和出版物（23）方面为ECOG提供更多资源。 CINJ最近还被批准为ECOG预防中心，并成为ECOG症状管理联盟的成员。 一些CINJ研究者已经获得了NCI-funded ECOG相关研究赠款的批准。 基于我们患者基础的持续增长（>4000例新病例/年），我们附属网络的增长（18家医院，> 14，000例新病例），以及我们对多个疾病领域ECOG累积的承诺，我们预计我们的累积，我们的科学和我们的管理角色将继续增长。 因此，CINJ将成为该集团较大的主要成员之一。 我们建议将这笔资金用于：1）继续代表我们参加ECOG疾病导向、行政和模式委员会; 2）设计并积极参与新的多模式研究; 3）提供同行评审、资助的机构实验室作为群体科学的潜在资源; 4）监测患者入组、方案依从性和数据质量; 5）及时提交完整的数据表，6）与其他ECOG成员合作，继续在CINJ开展试点研究;以及7）加强我们的基础科学实验室与集团临床试验计划之间的互动。